A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Proof-of-Concept Trial to Assess the Efficacy, Safety and Tolerability of Ascending Doses of Rotigotine Nasal Spray for the Acute Treatment of RLS Symptoms in Subjects With Idiopathic Restless Legs Syndrome.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Proof-of-Concept Trial to Assess the Efficacy, Safety and Tolerability of Ascending Doses of Rotigotine Nasal Spray for the Acute Treatment of RLS Symptoms in Subjects With Idiopathic Restless Legs Syndrome.

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Oct 2014

At a glance

  • Drugs Rotigotine (Primary)
  • Indications Restless legs syndrome
  • Focus Therapeutic Use
  • Sponsors UCB
  • Most Recent Events

    • 02 Jun 2009 Actual patient number (44) added as reported by ClinicalTrials.gov.
    • 02 Jun 2009 Actual end date (Dec 2006) added as reported by ClinicalTrials.gov.
    • 02 Jun 2009 Actual initiation date changed from Sep 2006 to Aug 2006 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top